Evidence map›Paper›PMID 40781582›Full record

ArticleClinical and translational allergy2025

Benralizumab Depletes IL-5Rα-Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis.

Christiane E Whetstone, Ruth P Cusack, Emma L Price, Karen J Howie, Caitlin Stevens, Dhuha Al-Sajee, Suzanne Beaudin, Jennifer Wattie, Nadia Alsaji, Abbey Schlatman and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03563066 (Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells.), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03563066 phase2completednot on this map

Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells.

TypeinterventionalSponsorMcMaster UniversityRan2018 to 2021Enrolled20ConditionsDermatitis, Atopic, Dermatitis, Eczema, Skin DiseasesArmsBenralizumab, Placebo Control
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Christiane E WhetstoneDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Ruth P CusackDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Emma L PriceDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Karen J HowieDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Caitlin StevensDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Dhuha Al-SajeeDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Suzanne BeaudinDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Jennifer WattieDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Nadia AlsajiDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Abbey SchlatmanDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Vanessa LukDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Paul M O'ByrneDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Mark D InmanDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Roma SehmiDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
Hermenio LimaDepartment of Medicine, Division of Allergy and Immunology, McMaster University, Hamilton, Ontario, Canada.
Gail M GauvreauDepartment of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.ORCID https://orcid.org/0000-0002-6187-2385

Funding

AstraZeneca Canada ESR-16-12430
6 · The paper itself

Abstract

backgroundAtopic dermatitis (AD) is a chronic inflammatory skin disease characterized by tissue eosinophilia and itch. We evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in the skin of patients with AD.

methodsAfter a 4-week washout from oral anti-inflammatory medications 20 patients with moderate to severe AD completed a randomized, double-blind, placebo-controlled parallel-group study comparing 3 doses q4wk 30 mg subcutaneous benralizumab to placebo. Lesional and unaffected skin biopsies were collected before and after 28 and 65 days of treatment, respectively, for quantification of eosinophils and IL-5Rα-bearing cells in papillary dermis. Histological measurements of epidermal thickness, spongiosis, neutrophilic and lymphocytic infiltration, as well as clinical scores EASI, SCORAD, IGA, DLQI, and POEM were conducted throughout the study. Outcomes were compared between placebo and benralizumab treatment groups using a Mann-Whitney U-test.

resultsBenralizumab, compared to placebo, reduced IL-5Rα+ cells and MBP+ EG2+ eosinophils in lesions and unaffected skin (p < 0.05). In skin lesions, benralizumab reduced MBP+ eosinophils and basophils but had no effect on eosinophil progenitor (EoP; CD34+ IL-5Rα+) or mast cell numbers. There was no change in other skin histological measurements or IGA scoring of the observational lesion, nor improvement in clinical scores.

conclusionBenralizumab treatment significantly inhibited accumulation of MBP+ eosinophils and basophils in lesional skin of patients with moderate to severe AD. However, a lack of improvement in histological and clinical outcomes suggests that other inflammatory pathways are central to the pathobiology of severe atopic dermatitis.

trial registration(ClincialTrials.gov number, NCT03563066).

Indexed as

atopic dermatitisbasophilsbenralizumabCD125eosinophilsmast cells

Identifiers

PMID40781582
PMCPMC12334360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.